Very-Low-Density Lipoproteins

Why This Matters

While chylomicrons transport dietary triglycerides, very-low-density lipoproteins (VLDL) transport triglycerides synthesized by the liver. VLDL is the body's principal mechanism for exporting excess energy from the liver to peripheral tissues. When hepatic triglyceride production increases, VLDL production also rises, making VLDL a central link between insulin resistance, metabolic syndrome, type 2 diabetes mellitus, fatty liver disease, and atherosclerotic cardiovascular disease — the same link this book's main chapters place at the center of the story.

What Is VLDL?

VLDL is a triglyceride-rich lipoprotein synthesized and secreted by the liver. Like chylomicrons, its primary function is to transport triglycerides to peripheral tissues. Unlike chylomicrons, which carry dietary fat, VLDL carries triglycerides produced within the liver from free fatty acids and de novo lipogenesis.

Each VLDL particle contains one molecule of apolipoprotein B-100, which remains attached throughout the particle's life cycle.

Why the Liver Produces VLDL

The liver continuously receives fatty acids from several sources. They may be released from adipose tissue, synthesized from excess dietary carbohydrate through de novo lipogenesis, or derived from dietary fat that has already been processed by the intestine.

Some of these fatty acids are oxidized to produce energy. Others are stored temporarily within hepatocytes. The remainder are assembled into triglycerides and packaged into VLDL for export to the circulation.

VLDL production therefore represents an essential physiological mechanism for preventing excessive accumulation of triglycerides within the liver.

VLDL Metabolism

After entering the circulation, VLDL acquires additional apolipoproteins from HDL, including ApoC-II and ApoE.

As VLDL passes through capillary beds in adipose tissue and muscle, lipoprotein lipase hydrolyzes its triglycerides, releasing free fatty acids for storage or energy production. Progressive triglyceride removal causes the particle to become smaller and denser.

During this remodeling process, VLDL is converted first into intermediate-density lipoprotein (IDL) and ultimately into low-density lipoprotein (LDL). Thus, most circulating LDL particles originate from VLDL produced by the liver.

VLDL and Insulin Resistance

Insulin normally suppresses the release of free fatty acids from adipose tissue and limits hepatic VLDL production.

As insulin resistance develops, this regulation becomes impaired. Increased lipolysis releases larger amounts of free fatty acids into the circulation, where they are taken up by the liver. At the same time, insulin resistance stimulates de novo lipogenesis, further increasing hepatic triglyceride synthesis.

The liver responds by producing more VLDL particles. The resulting increase in triglyceride-rich lipoproteins contributes to hypertriglyceridemia, low HDL cholesterol, and the formation of small, dense LDL particles — the lipid pattern most characteristic of insulin resistance, and the pattern this book's main chapters return to again and again.

VLDL and Atherosclerosis

Although VLDL is produced primarily to transport triglycerides, it is also an ApoB-containing lipoprotein capable of contributing to atherosclerosis.

Large VLDL particles are less likely to enter the arterial wall, but as they lose triglycerides and become smaller, they form remnant particles that readily penetrate the arterial intima. These remnants are rich in cholesterol and may become retained within the arterial wall, promoting inflammation and plaque formation.

The metabolism of VLDL also gives rise to LDL, further linking hepatic triglyceride overproduction to atherosclerotic cardiovascular disease.

Clinical Relevance

Increased VLDL production is a hallmark of insulin resistance and is a major contributor to hypertriglyceridemia.

Patients with obesity, metabolic syndrome, type 2 diabetes mellitus, and fatty liver disease frequently exhibit increased hepatic VLDL secretion. Elevated VLDL concentrations contribute not only to hypertriglyceridemia but also to the generation of remnant lipoproteins and small, dense LDL particles.

Reducing hepatic VLDL production through weight loss, improved insulin sensitivity, dietary modification, and appropriate pharmacologic therapy is a fundamental goal of treating diabetic dyslipidemia.

Clinical Pearls

• VLDL transports triglycerides synthesized by the liver.
• Each VLDL particle contains one ApoB-100 molecule.
• Most LDL particles are derived from VLDL.
• Increased VLDL production is a hallmark of insulin resistance.
• Excess hepatic VLDL contributes to hypertriglyceridemia, remnant accumulation, and small, dense LDL formation.

Common Misconceptions

Misconception: VLDL transports dietary fat.

Reality: Dietary triglycerides are transported by chylomicrons. VLDL transports triglycerides synthesized by the liver.

Misconception: VLDL exists only to carry triglycerides.

Reality: VLDL is also the precursor of IDL and LDL and contributes to the pool of circulating ApoB-containing lipoproteins.

Misconception: Elevated triglycerides are simply a laboratory abnormality.

Reality: Elevated triglycerides often reflect increased hepatic VLDL production, providing important insight into insulin resistance and underlying metabolic dysfunction.

Clinical Bottom Line

VLDL is the liver's mechanism for exporting triglycerides and distributing energy throughout the body. When hepatic triglyceride production increases, VLDL secretion rises, linking insulin resistance to hypertriglyceridemia, remnant lipoprotein accumulation, small, dense LDL formation, and ultimately atherosclerotic cardiovascular disease.